GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2007

Verus Could Earn $310M through Divestiture of Pediatric Asthma Programs to AstraZeneca

  • AstraZeneca acquired Verus Pharmaceuticals’ pediatric asthma development programs for $30 million. Verus will also receive development expense reimbursements and a potential earn-out payment of $280 million.

    Verus, a pediatric-oriented company, plans to refocus on developing therapeutics for unmet needs associated with related atopic diseases and conditions, comments Robert Keith, president and COO of the company.

    Through the transaction, AstraZeneca will gain North American rights to a Captisol® enabled budesonide solution, a short-acting beta agonist therapy, and a customized version of eFlow® for use with both medications.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?